Alatrofloxacin
A prodrug fluoroquinolone antibiotic that is converted in the body to trovafloxacin, a broad-spectrum antibacterial agent effective against a wide range of bacterial infections. It works by inhibiting bacterial DNA replication enzymes, preventing bacteria from reproducing and allowing the immune system to clear the infection.
Peso molecular
558,5000 g/mol
LogP
-0,20
TPSA
158,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]21
InChI
InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
Molecular Formula
C26H25F3N6O5
HBD / HBA
4 / 12
Enlaces Rotables
7
Átomos Pesados
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A prodrug fluoroquinolone antibiotic that is converted in the body to trovafloxacin, a broad-spectrum antibacterial agent effective against a wide range of bacterial infections. It works by inhibiting bacterial DNA replication enzymes, preventing bacteria from reproducing and allowing the immune system to clear the infection.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Yes, Alatrofloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201197. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3086677. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alatrofloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alatrofloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alatrofloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alatrofloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alatrofloxacin"></drugfyi-drug>